Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CLS006

Phase 3Small molecule

MMaruho Co., Ltd.

CLS006 is one of 12 small molecule programs targeting Common Wart. It is currently in Phase 3.

1

Indications

2

Total Trials

0

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

Common WartActive, not recruiting

Common WartPhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Common Wart

#DrugCompanyPhaseTrials

Vistide

Active

Deltavit

HHyundai Pharmaceutical Co., LTD.

Tuberculin Purified Protein Derivative

NNational Institute of Allergy and Infectious Diseases (NIAID)

Resiquimod

GGraceway Pharmaceuticals, LLC

CLS006

MMaruho Co., Ltd.

A-101

AAclaris Therapeutics, Inc.

Trexall

Alnylam Pharmaceuticals

PEP005

Candin

Johnson & Johnson

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Common Wart2 trials

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Completed·MMaruho Co., Ltd.·Phase 3·NCT03259620·491 enrolled

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Completed·MMaruho Co., Ltd.·Phase 3·NCT02971891·484 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CLS006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLS006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLS006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Maruho Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMaruho Co., Ltd.

Related News